SinoMab BioScience Limited

3681

HK0000544194

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.9 ^HKD	0.00%		+0.53%	+13.10%

Mar. 25	SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Feb. 07	SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	CI

SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2022

March 20, 2023 at 08:49 am EDT

SinoMab BioScience Limited reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was CNY 284.16 million compared to CNY 288.19 million a year ago. Basic loss per share from continuing operations was CNY 0.29 compared to CNY 0.29 a year ago.

Latest news about SinoMab BioScience Limited

SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director	Feb. 07	CI
SinoMab BioScience Raises HK$62.2 Million from Thirteen Share Subscriptions	Jan. 15	MT
SinoMab BioScience Issues 56.8 Million Shares to 15 Investors	Dec. 15	MT
SinoMab Doses First Batch of Subjects in Phase 1 Trial of Atopic Dermatitis Drug in China	Nov. 28	MT
SinoMab Bioscience Limited Announces First Cohort of the Health Subsidiaries Dosed in A Phase I Clinical Trial of SM17 in China	Nov. 27	CI
China Accepts Clinical Trial Application for SinoMab BioScience's Alzheimer's Treatment; Shares Rise 3%	Nov. 15	MT
Sinomab Bioscience Limited Announces IND Application for SM03 (Suciraslimab) for the Treatment of Alzheimer's Disease Accepted by NMPA CDE	Nov. 15	CI
China Accepts New Drug Application of SinoMab's Dermatitis Medication; Shares Rise 3%	23-09-11	MT
Sinomab Bioscience Limited announces Change of Non-Executive Directors	23-09-06	CI
Chinese Regulator Accepts License Application for SinoMab's Arthritis Drug	23-09-05	MT
China Accepts SinoMab's Biologics License Application for Arthritis Treatment	23-09-05	MT
SinoMab BioScience Limited Announces National Medical Products Administration Accepts Biologics License Application for SM03 in the Treatment of Rheumatoid Arthritis	23-09-05	CI
SinoMab Bioscience to Shrink Loss in H1	23-08-22	MT
SinoMab BioScience Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-21	CI
SinoMab Bioscience Obtains Clinical Trial Approval in China for Asthma Drug	23-08-15	MT
Sinomab Bioscience Limited Announces IND Approval for Sm17 by Nmpa	23-08-14	CI
Sinomab Bioscience Limited Announces IND Application for SM17 Accepted by NMPA CDE	23-06-12	CI
Chinese Regulator Accepts SinoMab's Investigational New Drug Application for Asthma Treatment	23-05-21	MT
SinoMab BioScience Limited Announces Filing and Acceptance of Investigational New Drug Application for SM17 by the Center for Drug Evaluation of the National Medical Products Administration of China	23-05-21	CI
SinoMab Bioscience Achieves Primary Endpoints for Phase III Clinical Study of Rheumatoid Arthritis Treatment; Shares Cimb 4%	23-04-27	MT
SinoMab BioScience Limited Announces Phase III Clinical Trial of its Product SM03 (Suciraslimab) Achieves the Primary Endpoint for Rheumatoid Arthritis	23-04-26	CI
SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
SinoMab Bioscience Unit's Rent in Haiyao Industrial Park Rises to 9.4 Million Yuan	22-12-02	MT
Hainan Sinomab Enters into A Supplemental Lease Agreement with Haikou Pharma Pursuant to Which the Annual Rental of the Property	22-12-01	CI

Chart SinoMab BioScience Limited

Duration

Period

More charts

Company Profile

SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The Companyâs product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogrenâs syndrome (SS) and other immunological diseases.

Sector

Pharmaceuticals

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
SINOMAB BIOSCIENCE LIMITED	+13.10%	265M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.36B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B